10 Best Cancer Stocks to Invest in for Long-Term Gains
After cardiovascular disease, cancer is the second most common cause of mortality worldwide.
Krystal Biotech Inc. (KRYS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | HealthInvest Partners AB Anders Hallberg And Carl Bennet | 20,158 | $2,770,919 | -15% | 1.19% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.00 | 25,000 | $500,000.00 | 2,001,462 | 2018-10-18 | Filing | |
| $20.00 | 25,000 | $500,000.00 | 2,036,462 | 2018-10-18 | Filing | |
| $12.45 | 1,018 | $12,674.10 | 1,976,462 | 2018-06-06 | Filing | |
| $11.15 | 13,116 | $146,177.82 | 1,975,444 | 2018-06-06 | Filing | |
| $10.75 | 10,866 | $116,757.34 | 1,962,328 | 2018-06-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $151.39 | 300 | $45,416.01 | 1,525,929 | 2025-07-10 | Filing | |
| $150.22 | 6,627 | $995,497.34 | 1,526,229 | 2025-07-10 | Filing | |
| $150.07 | 200 | $30,014.00 | 1,532,856 | 2025-07-09 | Filing | |
| $151.39 | 300 | $45,416.01 | 1,456,711 | 2025-07-10 | Filing | |
| $150.23 | 6,500 | $976,463.80 | 1,457,011 | 2025-07-10 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,863 | $256,088 | 0.01% | |
| 2. | 1,182 | $162,478 | 0.01% | |
| 3. | 941 | $129,350 | 0% | |
| 4. | 285 | $39,176 | 0% | |
| 5. | 100 | $13,746 | 0.01% |
News See All
Krystal Biotech, Inc. (NASDAQ:KRYS) Q1 2025 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to the Krystal Biotech First Quarter 2025 Earnings Call. At this time, all participants are on a listen-only mode.
Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2024 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to the Krystal Biotech Q4 2024 Earnings Call. At this time, all participants are on a listen-only mode.
Krystal Biotech, Inc. (NASDAQ:KRYS) Q3 2024 Earnings Call Transcript
Operator: Thank you for standing by and welcome to Krystal Biotech's Third Quarter Earnings Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded.
10 Worst Booming Stocks to Buy According to Short Sellers
September has historically been one of the worst months for US stocks.
Krystal Biotech (KRYS) Surged as it Beat the Streat Estimates with Wide Margin
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” first-quarter 2024 investor letter.
Is Krystal Biotech, Inc. (NASDAQ:KRYS) the Premier Gene Therapy Stock for Your Portfolio?
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Krystal Biotech, Inc.
9 Best Gene Therapy Stocks to Buy Now
In this article, we will be discussing the best gene therapy stocks to buy now. Before we move on to our list, let's take a look at the market outlook for gene therapies and understand the reasons behind...
Krystal Biotech, Inc. (NASDAQ:KRYS) Q1 2024 Earnings Call Transcript
Krystal Biotech, Inc. misses on earnings expectations. Reported EPS is $0.03182 EPS, expectations were $0.2. Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2023 Earnings Call Transcript
Operator: Thank you for standing by and welcome to the Krystal Biotech Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time, all participants are on a lesson-only mode.
Billionaire Hedge Funds
